American Association for Cancer Research
10780432ccr121060-sup-f1_pdf_72k.pdf (72.74 kB)

Supplementary Figure 1 from PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas

Download (72.74 kB)
journal contribution
posted on 2023-03-31, 17:29 authored by Katherine Walsh, Matthew S. McKinney, Cassandra Love, Qingquan Liu, Alice Fan, Amee Patel, Jason Smith, Anne Beaven, Dereje D. Jima, Sandeep S. Dave

PDF file - 72 KB, Supplementary Figure S1 shows the results for the experiment to determine if there was a therapeutic window between malignant and normal cells. Both IPA-3 and BEZ235 individually and in combination were selectively toxic to malignant B cells (Ly8 cell line) compared to normal B cells.



Purpose: The phosphoinositide 3-kinase (PI3K) pathway is known to play an active role in many malignancies. The role of PI3K inhibition in the treatment of lymphomas has not been fully delineated. We sought to identify a role for therapeutic PI3K inhibition across a range of B-cell lymphomas.Experimental Design: We selected three small molecule inhibitors to test in a panel of 60 cell lines that comprised diverse lymphoma types. We tested the selective PI3K inhibitor BKM120 and the dual PI3K/mTOR inhibitors BEZ235 and BGT226 in these cell lines. We applied gene expression profiling to better understand the molecular mechanisms associated with responsiveness to these drugs.Results: We found that higher expression of the PAK1 gene was significantly associated with resistance to all three PI3K inhibitors. Through RNA–interference-mediated knockdown of the PAK1 gene, we showed a dramatic increase in the sensitivity to PI3K inhibition. We further tested a small-molecule inhibitor of PAK1 and found significant synergy between PI3K and PAK1 inhibition.Conclusion: Thus, we show that PI3K inhibition is broadly effective in lymphomas and PAK1 is a key modulator of resistance to PI3K inhibition. Clin Cancer Res; 19(5); 1106–15. ©2012 AACR.